Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cantargia’s Phase 1 Shows CAN10 PK/PD Supports Monthly Phase 2 Dosing
Details : The CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36.
Product Name : CAN10
Product Type : Antibody
Upfront Cash : Inapplicable
May 12, 2025
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cantargia's CAN10 Shows Promise in First Multiple Dose Cohort
Details : CAN10 is an antibody targeting IL1RAP and is currently being evaluated in a Phase 1 clinical trial for the treatment of plaque psoriasis.
Product Name : CAN10
Product Type : Antibody
Upfront Cash : Inapplicable
March 05, 2025
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cantargia Expands the CAN10 Phase 1 Clinical Program Building On Positive Results
Details : CAN10 is an antibody targeting IL1RAP and is currently being evaluated in a Phase 1 clinical trial for the treatment of plaque psoriasis.
Product Name : CAN10
Product Type : Antibody
Upfront Cash : Inapplicable
November 29, 2024
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cantargia Reports Positive Biomarker And Safety Data in CAN10 Phase 1 Study
Details : CAN10 antibody binds strongly to its target IL1RAP and has a unique capability to inhibit signaling via IL-1, IL-33 and IL-36 for the treatment of several inflammatory or autoimmune diseases.
Product Name : CAN10
Product Type : Antibody
Upfront Cash : Inapplicable
November 10, 2024
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cantargia Reports Progress and Biomarker Data from Phase 1 CAN10 Trial
Details : The CAN10 antibody binds to IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36. It is under clinical development for the treatment of Plaque Psoriasis.
Product Name : CAN10
Product Type : Antibody
Upfront Cash : Inapplicable
September 08, 2024
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cantargia Reports Phase I Clinical Progress in the CAN10 Project
Details : The CAN10 antibody targets IL1RAP and inhibits signaling via IL-1, IL-33, and IL-36, currently in phase 1 trials for plaque psoriasis.
Product Name : CAN10
Product Type : Antibody
Upfront Cash : Inapplicable
September 01, 2024
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cantargia Reports Further Progress in Ongoing Phase 1 Clinical Trial with CAN10
Details : The CAN10 antibody binds to IL1RAP and has a unique capability to simultaneously inhibit signaling via IL-1, IL-33 and IL-36. It is under clinical development for the treatment of Plaque Psoriasis.
Product Name : CAN10
Product Type : Antibody
Upfront Cash : Inapplicable
June 14, 2024
Lead Product(s) : CAN10
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ensereptide
Therapeutic Area : Dermatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Promore Pharma Provides an Update on the Phase II Clinical Trial with Ensereptide
Details : The company's ensereptide program is currently focused on the prevention of skin scarring associated with surgery or trauma. In the spring, a total of 24 subjects completed the clinical study protocol according to plan in the phase II study with enserept...
Product Name : PXL01
Product Type : Peptide
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : Ensereptide
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable